Skip to main content

Table 3 Treatment-emergent adverse events reported by at least 20% of patients and grade 3 and higher incidence of these events

From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Event term Treatment-emergent adverse events (any grade) Any grade 3 events Any grade 4 events Any grade 5 events
Any event, n (%) 28 (97) 8 (28) 3 (10) 3 (10)
Peripheral sensory neuropathy 17 (59) 2 (7) 0 0
Fatigue 12 (41) 3 (10) 1 (3) 0
Nausea 12 (41) 1 (3) 0 0
Diarrhea 11 (38) 0 0 0
Arthralgia 8 (28) 2 (7) 0 0
Headache 8 (28) 0 0 0
Peripheral motor neuropathy 8 (28) 2 (7) 0 0
Pyrexia 8 (28) 0 0 0
Anemia 7 (24) 5 (17) 0 0
Dyspnea 7 (24) 1 (3) 1 (3) 0
Back pain 6 (21) 1 (3) 0 0